Announces $2.5 million endowed dermatology professorship at Mount Sinai

Sun Pharma has announced the setting up of the "Sun Professorship in Dermatology" at the Icahn School of Medicine at Mount Sinai, USA.

Tue 6 Oct 2026

Endowment Amount

$2.5 million endowment from Sun Pharma

Inaugural Professor

Mark G. Lebwohi, MD, is installed as the inaugural professor

Institution

Icahn School of Medicine at Mount Sinai, USA

What has been announced

Sun Pharmaceutical Industries Limited has announced the establishment of the "Sun Professorship in Dermatology" at the Icahn School of Medicine at Mount Sinai, USA. Mark G. Lebwohi, MD, will be installed as the inaugural professor at a ceremony held at Hatch Auditorium at The Mount Sinai Hospital in New York.

The money involved

• The professorship is supported by a $2.5 million endowment from Sun Pharma.
• The endowment is meant to fund academic leadership in dermatology in perpetuity, beginning with Dr. Lebwohi as its inaugural incumbent.

What the professorship will do

• It will be based within the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai.
• It will advance research and training, help translate emerging knowledge into better care, and prepare future leaders in the field.

About the inaugural professor

Dr. Lebwohi serves as Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai and Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology. He is recognised for his contributions to psoriasis research and treatment and served as President of the American Academy of Dermatology from 2015 to 2016.

Why dermatology matters to the company

• Sun Pharma describes itself as the second-largest pharmaceutical dermatology company in the U.S. by prescription volume.
• Its Global Innovative Medicines portfolio spans dermatology, ophthalmology and oncodermatology and accounts for about 22% of company sales.
• The company says it is present in over 100 countries, has manufacturing facilities across five continents, and a workforce drawn from over 50 nations.

How a retail investor can read this

• This is a company-funded academic endowment. It is a spending commitment, not an order, revenue or a product approval.
• The stated benefit is long-term: support for research, education and mentorship in dermatology, and an association with a leading academic medical institution in the company's core specialty.
• It sits alongside the company's own description of its position in dermatology and the share of sales coming from its Global Innovative Medicines portfolio.
• The announcement does not change the share count, the capital structure or any regulatory approval of the company's products.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.